0
No votes yet

Aromatase Inhibitor Agents in Breast Cancer: Evolving Practices in Hormonal Therapy Treatment

Pamela Hallquist Viale
ONF 2005, 32(2), 343-353 DOI: 10.1188/05.ONF.343-353

Purpose/Objectives: To review the role of aromatase inhibitor agents with regard to current treatment strategies with hormonal therapy for women with breast cancer.

References 

American Cancer Society. (2005). Cancer facts and figures 2004. Retrieved February 15, 2005, from http://www.cancer.org/docroot/STT/stt_0.asp

Banerjee, M., George, J., Song, E.Y., Roy, A., & Hryniuk, W. (2004). Tree-based model for breast cancer prognostication. Journal of Clinical Oncology, 22, 2567-2575.

Baum, M., Buzdar, A., Cuzick, J., Forbes, J., Houghton, J., Howell, A., et al. (2003). Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimdex, tamoxifen alone or in combination) trial efficacy and safety update analyses. Cancer, 98, 1802-1810.

Baum, M., Budzar, A.U., Cuzick, J., Forbes, J., Houghton, J.H., Klijn, J.G., et al. (2002). Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet, 359, 2131-2139.

Bernstein, L., Deapen, D., Cerhan, J.R., Schwartz, S.M., Liff, J., McGann-Maloney, E., et al. (1999). Tamoxifen therapy for breast cancer and endometrial cancer risk. Journal of the National Cancer Institute, 91, 1654-1662.

BIG 1-98 Collaborative Group. (2005, January). Letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. BIG 1-98: A prospective randomized double-blind phase III study. Abstract presented at the Primary Therapy of Early Breast Cancer 9th International Conference, St. Gallen, Switzerland.

Boccardo, F., Rubagotti, A., Amoroso, D., Mesiti, M., Massobrio, M., Benedetto, C., et al. (2003, December). Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment [Abstract 3]. Presentation at the San Antonio Breast Symposium, San Antonio, TX.

Boccardo, F., Rubagotti, A., Amoroso, D., Mesiti, M., Romeo, D., Caroti, C., et al. (2001). Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: Results of an Italian cooperative study. Journal of Clinical Oncology, 19, 4209-4215.

Bonneterre, J., Thurlimann, B., Robertson, J.F., Krzakowski, M., Mauriac, L., Koralewski, P., et al. (2000). Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. Journal of Clinical Oncology, 18, 3748-3757.

Bryant, J., & Wolmark, N. (2003). Letrozole after tamoxifen for breast cancer—What is the price of success? New England Journal of Medicine, 349, 1855-1857.

Burstein, H.J. (2003). Beyond tamoxifen—Extending endocrine treatment for early-stage breast cancer. New England Journal of Medicine, 349, 1857-1859.

Buzdar, A.U. (2003a). Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer. Oncologist, 8, 335-341.

Buzdar, A.U. (2003b). Aromatase inhibitors in breast cancer therapy. Clinical Breast Cancer, 4(Suppl. 2), S84-S88.

Buzdar A.U. (2004a). Data from the Arimidex, Tamoxifen Alone or in Combination (ATAC) trial: Implications for use of aromatase inhibitors in 2003. Clinical Cancer Research, 10(1, Pt. 2), 355S-361S.

Budzar, A.U. (2004b). Hormonal therapy in early and advanced breast cancer. Breast Journal, 10(Suppl. 1), S19-S21.

Campos, S.M. (2004). Aromatase inhibitors for breast cancer in postmenopausal women. Oncologist, 9, 126-136.

Chung, C.T., & Carlson, R.W. (2003). The role of aromatase inhibitors in early breast cancer. Current Treatment Options in Oncology, 4, 133-140.

Clemons, M., & Goss, P. (2001). Estrogen and the risk of breast cancer. New England Journal of Medicine, 344, 276-285.

Coombes, R.C., Hall, E., Gibson, L.J., Paridaens, R., Jassem, J., Delozier, T., et al. (2004). A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. New England Journal of Medicine, 350, 1081-1092.

Fisher, B., Dignam, J., Bryant, J., & Wolmark, N. (2001). Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. Journal of the National Cancer Institute, 93, 684-690.

Fleming, T. (Ed.). (2004). Red book [2004 edition]. Montvale, NJ: Thomson Health Care.

Goss, P.E., Ingle, J.N., Marino, S., Robert, N.J., Muss, H.B., Piccart, M.J., et al. (2003). A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. New England Journal of Medicine, 349, 1793-1802.

Goss, P.E., & Strasser, K. (2001). Aromatase inhibitors in the treatment and prevention of breast cancer. Journal of Clinical Oncology, 19, 881-894.

Grana, G. (2003). New developments in endocrine therapy: Role of adjuvant therapy for early breast cancer. Cancer Nursing, 26(6, Suppl.), 4S-9S.

Hayes, D.F. (2004). Tamoxifen: Dr. Jekyll and Mr. Hyde? Journal of the National Cancer Institute, 96, 895-897.

Hortobagyi, G.N. (1998). Treatment of breast cancer. New England Journal of Medicine, 339, 974-984.

Ingle, J.N. (2003). Adjuvant endocrine therapy in postmenopausal breast cancer. Clinical Cancer Research, 9(1, Pt. 2), 480S-485S.

Lake, D.E., & Hudis, C. (2002). Aromatase inhibitors in breast cancer: An update. Cancer Control, 9, 490-498.

Lieff Cabraser Heimann & Bernstein, LLP. (n.d.). Tamoxifen/Nolvadex. Retrieved January 25, 2005, from http://www.prescription-drugs-lawsuits.com/tamoxifen.htm

Lynn, J. (2002). The oncology nurse's role in educating patients on endocrine therapy for metastatic breast cancer—Focus on fulvestrant. Cancer Nursing, 25(Suppl. 2), 12S-17S.

Major, M.A. (2003). Clinical trials update: Medical management of advanced breast cancer. Cancer Nursing, 26(6, Suppl.), 10S-15S.

Maxwell, C., & Viale, P.H. (in press). Cancer treatment-induced bone loss in patients with breast and prostate cancer. Oncology Nursing Forum.

Mouridsen, H., Gershanovich, M., Sun, Y., Perez-Carrion, R., Boni, C., Monnier, A., et al. (2001). Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. Journal of Clinical Oncology, 19, 2596-2606.

Mouridsen, H.T., Rose, C., Brodie, A.H., & Smith, I.E. (2003). Challenges in the endocrine management of breast cancer. Breast, 12(Suppl. 2), S2-S19.

Nabholtz, J.M., Buzdar, A., Pollak, M., Harwin, W., Burton, G., Mangalik, A., et al. (2000). Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. Journal of Clinical Oncology, 18, 3758-3767.

National Comprehensive Cancer Network. (2005). National Comprehensive Cancer Network practice guidelines in oncology: Breast cancer—v. 1.2005. Retrieved January 28, 2005, from http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf

Palmieri, F.M., & Perez, E.A. (2003). Recent advances in adjuvant therapy for breast cancer. Seminars in Oncology Nursing, 19(4, Suppl. 2), 10-16.

Piccart-Gebhart, M.J. (2004). New stars in the sky of treatment for early breast cancer. New England Journal of Medicine, 350, 1140-1142.

Schiff, R., Massarweh, S.A., Shou, J., Bharwani, L., Mohsin, S.K., & Osborne, C.K. (2004). Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clinical Cancer Research, 10(1, Pt. 2), 331S-336S.

Serrano, D., Perego, E., Costa, A., &, Decensi, A. (2004). Progress in chemoprevention of breast cancer. Critical Reviews in Oncology/Hematology, 49, 109-117.

Smith, I.E., & Dowsett, M. (2003). Aromatase inhibitors in breast cancer. New England Journal of Medicine, 348, 2431-2442.

Spratto, G.R., & Woods, A.L. (2004). 2004 PDR nurses drug handbook. Clifton Park, NY: Delmar Learning.

U.S. Food and Drug Administration. (2004). New approvals: Drugs and biologicals. Retrieved November 29, 2004, from http://www.fda.gov/cder/cancer/whatsnew.htm

Versea, L., & Rosenzweig, M. (2003). Hormonal therapy for breast cancer: Focus on fulvestrant. Clinical Journal of Oncology Nursing, 7, 307-311.

Viale, P.H., & Yamamoto, D.S. (2003). Bisphosphonates: Expanded roles in the treatment of patients with cancer. Clinical Journal of Oncology Nursing, 7, 393-401.

Wilkinson, K. (2004). Anastrozole (Arimidex®). Clinical Journal of Oncology Nursing, 8, 87-88.

Winer, E.P., Hudis, C., Burstein, H.J., Bryant, J., Chlebowski, R.T., Ingle, J.N., et al. (2003). American Society of Clinical Oncology technology assessment working group update: Use of aromatase inhibitors in the adjuvant setting. Journal of Clinical Oncology, 21, 2597-2599.

Winer, E.P., Hudis, C., Burstein, H.J., Chlebowski, R.T., Ingle, J.N., Edge, S.B., et al. (2002). American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: Status report 2002. Journal of Clinical Oncology, 20, 3317-3327.

Winer, E.P., Hudis, C., Burstein, H.J., Wolff, A.C., Pritchard, K.I., Ingle, J.N., et al. (2004). American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. Journal of Clinical Oncology, 23, 619-629.